Search results for
5187 items
Equality and Human Rights Consultation - NICE TA - Sofosbuvir-velpatasvir for Treating Chronic Hepatitis C
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pembrolizumab for Treating PD-L1-Positive Non-Small-Cell Lung Cancer after Platinum-Based Chemotherapy
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Mepolizumab for Treating Severe Eosinophilic Asthma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Ibrutinib for Previously Treated Chronic Lymphocytic Leukaemia and Untreated Chronic Lymphocytic Leukaemia with 17p Deletion or TP53 Mutation
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma (review of TA338)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Dasatinib, Nilotinib and Imatinib for Untreated Chronic Myeloid Leukaemia (Part Review of TA251)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Dasatinib, Nilotinib and High-Dose Imatinib for Treating Imatinib-Resistant or Intolerant Chronic Myeloid Leukaemia (Part Review of TA241) - Section 75 Questionnaire
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pertuzumab for the Neoadjuvant Treatment of HER2-Positive Breast Cancer
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Everolimus with Exemestane for Treating Advanced Breast Cancer after Endocrine Therapy
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction [ID813]
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens (Review of TA250) [ID964]
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Nivolumab for Treated or Metastatic Renal Cell Carcinoma [ID853]
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Certolizumab Pegol for Treating Rheumatoid Arthritis after Inadequate Response to a TNF Inhibitor
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Elbasvir-grazoprevir for treating chronic hepatitis C
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases (Review of TA376)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Aflibercept for Treating Visual Impairment caused by Macular Oedema after Branch Retinal Vein Occlusion
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the